Black Diamond Therapeutics (BDTX) Net Cash Flow Growth (3y) (2022 - 2026)

Black Diamond Therapeutics (BDTX) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -50.33%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.47%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -29.82%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Black Diamond Therapeutics 99.59 Mn -18.67 Mn - 23.47%

Historic Data

Download Data
DateValue
Mar 31, 2026 23.47%
Dec 31, 2025 20.50%
Sep 30, 2025 34.92%
Jun 30, 2025 -245.67%
Mar 31, 2025 93.90%
Dec 31, 2024 -12.17%
Sep 30, 2024 -44.40%
Jun 30, 2024 -31.72%
Mar 31, 2024 -14.54%
Dec 31, 2023 56.70%
Sep 30, 2023 63.48%
Jun 30, 2023 26.19%
Mar 31, 2023 -71.22%
Dec 31, 2022 -31.20%
Sep 30, 2022 -27.02%
Jun 30, 2022 32.83%
Mar 31, 2022 -19.38%